| About Novartis Vaccines | Products | Pipeline | Press Room | Locations |
New technologies have made it possible to develop improved vaccines - and Novartis Vaccines is a world leader in this revolution. Novartis provides innovative vaccines alongside a wide range of conventional products to combat diseases across the globe.
MENINGITIS VACCINESNovartis's leadership was proven in the battle against meningococcal C disease in vaccination campaigns in the UK, Ireland, Quebec/Canada, Australia and Spain. Menjugate has helped to reduce the incidence of Meningococcal C disease in the UK by 87% and to decrease the number of deaths caused by Neisseria meningitidis C* by 92,5%.
*Balmer et al. 2002. Impact of menogoccocal C conjugate vaccine in the UK. Journal of Med. Microbiol. Vol. 51, 717-722.
INFLUENZA VACCINESNovartis offers a unique portfolio of Influenza vaccines designed to serve individual patients' needs. The expertise and experience of Novartis scientists is reflected in these high-quality products, each of which is tailored to specific patient groups with different needs.
TRAVEL VACCINESNovartis Vaccines produces some of the world's most widely used vaccines against diseases of particular concern to travelers, e.g. rabies and Tick-borne Encephalitis.
PEDIATRIC VACCINESChildren around the world benefit from Novartis Vaccines' pediatric products. Through partnerships with the World Health Organization, the Global Alliance for Vaccines and Immunization and other groups, Novartis helps to protect young people from measles, mumps, polio and other diseases.
ADULT VACCINESThese Novartis vaccines have protected millions of adults from life-threatening illness.
NOTE:
Products presented on this website are subject to national regulatory approval, licensing and advertising rules which differ from country to country.
These products may not be approved and/or licensed in all countries where this website is accessible and, with the exception of Fluvirin® and RabAvert®, have not been approved by the U.S. Food and Drug Administration.
In jurisdictions where the presentation and advertising of our products is restricted to members of the medical profession and pharmaceutical organization, such presentation and advertising as are found on this site are not intended for the public and should not be accessed by users who are not members of a medical profession or pharmaceutical organization.
These products, with the exception of Fluvirin® and RabAvert®, are not intended for use by customers, patients or health care professionals in the United States.
Members of the medical profession and pharmaceutical trade are requested not to use this website for any purpose regulated by their respective national laws such as drug approval information, license information, health product promotion or any other purpose for which this international website is not intended.
    |
  |
  |
US Medical Communications is the point of contact for inquiries about our marketed vaccine products, pipeline products, and general vaccine-related questions. Business hours are 8:00am - 5:00pm Eastern Time. Call or submit your question online.
1-800-244-7668, Option 2
FLUVIRIN® Influenza Virus Vaccine is now available for online ordering in the U.S. Please visit the Novartis Vaccines Direct website to place your order today.
